Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2003 
         Financial Results on Thursday, August 14, at 10:00 a.m. EDT 
 
    NEW YORK, Aug. 7 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London 
AIM: KRX) will hold a conference call at 10:00 a.m. EDT on Thursday, August 14, 
2003.  Michael S. Weiss, Chairman and Chief Executive Officer of the Company, 
will host the call.  Mr. Weiss will discuss the Company's second quarter results 
for 2003, as well as provide an update on the Company's projects.  Keryx expects 
to announce its financial results for this period in a press release to be 
issued before the opening of the market on Wednesday, August 13, 2003. 
    In order to participate in the conference call, please call 1-866-527-8676 
(U.S.) ID Code: Keryx, 1-866-485-2399 (Canada), 1-800-227-297 (Israel),  
0-800-917-4613 (UK), 0-800-903-025 (France), 0-800-563-309 (Switzerland), and 
0-800-182-6846 (Germany). 
    The press release announcing our financial results for the second quarter 
of 2003 can be accessed by visiting the Company's website at www.keryx.com 
starting on Wednesday, August 13, 2003.  The conference call will also will be 
available for audio replay at www.keryx.com, for a period of 15 days after the 
call. 
 
    ABOUT KERYX BIOPHARMACEUTICALS, INC. 
    Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX) is a 
biopharmaceuticals company focused on the acquisition, development and 
commercialization of novel pharmaceutical products for the treatment of 
serious, life-threatening diseases, including diabetes and cancer.  Keryx is 
developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid 
compound, for the treatment of diabetic nephropathy, for which Keryx is 
currently planning its U.S.-based Phase II/III clinical program.  Keryx also 
has an active in-licensing program designed to identify and acquire clinical-
stage drug candidates.  Additionally, Keryx is seeking partners for its 
KinAce(TM) drug discovery technology and related products.  Keryx 
Biopharmaceuticals is headquartered in New York City. 
 
     KERYX CONTACT: 
     Ron Bentsur 
     Vice President, Finance & Investor Relations 
     Keryx Biopharmaceuticals, Inc. 
     Tel: 212-531-5965 
     E-mail: ron@keryx.com 
 
SOURCE  Keryx Biopharmaceuticals, Inc. 
    -0-                             08/07/2003 
    /CONTACT:  Ron Bentsur, Vice President, Finance & Investor Relations of 
Keryx Biopharmaceuticals, Inc., +1-212-531-5965, ron@keryx.com/ 
    /Web site:  http://www.keryx.com / 
    (KERX) 








END